tbuckley/cabot-search huggingface dataset:
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression
Authors: G. Bronte, M. Puccetti, L. Crinò, S. Bravaccini
Journal: Annals of Oncology (2018)

In a recent article by Lindsay et al. published in Annals of Oncology, vimentin expression was detected in circulating tumor cells (CTCs) from patients with non-small-cell lung cancer [1]. The authors reported a significant difference in the percentage of patients with vimentin-positive CTCs between epidermal growth factor receptor (EGFR)-mutant and EGFR-wild-type disease. However, such a substantial difference was not observed for other oncogenic drivers, e.g. ALK-rearrangement and KRAS mutations.
P04.05 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma
Authors: M. C. Burger, I. Mildenberger, C. Zhang, K. Ihrig, M. Wagner, M. Mittelbronn, C. Senft, T. Tonn, W. S. Wels, J. P. Steinbach
Journal: Neuro-Oncology (2016)
Rapid Generation of Multivirus-Specific T Lymphocytes for the Prevention and Treatment of Respiratory Viral Infections
Authors: Spyridoula Vasileiou, Annie Turney, Manik Kuvalekar, Shivani Mukhi, Ayumi Watanabe, Premal Lulla, Carlos A. Ramos, Juan Vera, Ifigeneia Tzannou, Ann Leen
Journal: Blood (2018)
TEAD1 (TEA Domain Transcription Factor 1) Promotes Smooth Muscle Cell Proliferation Through Upregulating SLC1A5 (Solute Carrier Family 1 Member 5)-Mediated Glutamine Uptake
Authors: Islam Osman, Xiangqin He, Jinhua Liu, Kunzhe Dong, Tong Wen, Fanzhi Zhang, Luyi Yu, Guoqing Hu, Hongbo Xin, Wei Zhang, Jiliang Zhou
Journal: Circulation Research (2019)

TEAD (TEA domain transcription factor) 1-a major effector of the Hippo signaling pathway-acts as an oncoprotein in a variety of tumors. However, the function of TEAD1 in vascular smooth muscle cells (VSMCs) remains unclear. To assess the role of TEAD1 in vascular injury-induced smooth muscle proliferation and delineate the mechanisms underlying its action. We found that TEAD1 expression is enhanced in mouse femoral artery after wire injury and correlates with the activation of mTORC1 (mechanistic target of rapamycin complex 1) signaling in vivo. Using an inducible smooth muscle-specific Tead1 KO (knockout) mouse model, we found that specific deletion of Tead1 in adult VSMCs is sufficient to attenuate arterial injury-induced neointima formation due to inhibition of mTORC1 activation and VSMC proliferation. Furthermore, we found that TEAD1 plays a unique role in VSMCs, where it not only downregulates VSMC differentiation markers but also activates mTORC1 signaling, leading to enhanced VSMC proliferation. Using whole-transcriptome sequencing analysis, we identified Slc1a5 (solute carrier family 1 member 5)-a key glutamine transporter-as a novel TEAD1 target gene. SLC1A5 overexpression mimicked TEAD1 in promoting mTORC1 activation and VSMC proliferation. Moreover, depletion of SLC1A5 by silencing RNA or blocking SLC1A5-mediated glutamine uptake attenuated TEAD1-dependent mTORC1 activation and VSMC proliferation. Our study unravels a novel mechanism by which TEAD1 promotes VSMC proliferation via transcriptional induction of SLC1A5, thereby activating mTORC1 signaling and promoting neointima formation.
Improvement of the Six-Minute Walk Test in Children with Sickle Cell Disease over Time
Authors: Geoffrey Bourg, Laurence Dedeken, Phu-Quoc Le, Laurence Rozen, Safiatou Diallo, Sabine Amah, Christine Devalck, Catherine Heijmans, Laurence Hanssens, Rossana Pavone, Malou Ngalula Mujinga, Alina Ferster
Journal: Blood (2018)
Combined Pharmacological Inhibition of Bruton's Tyrosine Kinase (BTK) and Phosphoinositide 3-Kinase (PI3K) p110δ Rescues Monocytosis, Thrombocytopenia, and Splenomegaly in a Genetic Mouse Model for JMML
Authors: Roshni Patel, Baskar Ramdas, Lisa Deng, Victoria Jideonwo-Auman, Rebecca J Chan, Reuben Kapur
Journal: Blood (2018)
Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation
Authors: Ersilia M. DeFilippis, Lauren K. Truby, A. Reshad Garan, Raymond C. Givens, Koji Takeda, Hiroo Takayama, Yoshifumi Naka, Jennifer H. Haythe, Maryjane A. Farr, Veli K. Topkara
Journal: JACC Heart Failure (2019)
Endometriosis and nuclear receptors
Authors: Bahar D Yilmaz, Serdar E Bulun
Journal: Human Reproduction Update (2019)

Endometriosis is recognized as a steroid-dependent disorder; however, the precise roles of nuclear receptors (NRs) in steroid responsiveness and other signaling pathways are not well understood.Over the past several years, a number of paradigm-shifting breakthroughs have occurred in the area of NRs in endometriosis. We review and clarify new information regarding the mechanisms responsible for: (i) excessive estrogen biosynthesis, (ii) estrogen-dependent inflammation, (iii) defective differentiation due to progesterone resistance and (iv) enhanced survival due to deficient retinoid production and action in endometriosis. We emphasize the roles of the relevant NRs critical for these pathological processes in endometriosis.We conducted a comprehensive search using PubMed for human, animal and cellular studies published until 2018 in the following areas: endometriosis; the steroid and orphan NRs, estrogen receptors alpha (ESR1) and beta (ESR2), progesterone receptor (PGR), steroidogenic factor-1 (NR5A1) and chicken ovalbumin upstream promoter-transcription factor II (NR2F2); and retinoids.Four distinct abnormalities in the intracavitary endometrium and extra-uterine endometriotic tissue underlie endometriosis progression: dysregulated differentiation of endometrial mesenchymal cells, abnormal epigenetic marks, inflammation activated by excess estrogen and the development of progesterone resistance. Endometriotic stromal cells compose the bulk of the lesions and demonstrate widespread epigenetic abnormalities. Endometriotic stromal cells also display a wide range of abnormal NR expression. The orphan NRs NR5A1 and NR2F2 compete to regulate steroid-synthesizing genes in endometriotic stromal cells; NR5A1 dominance gives rise to excessive estrogen formation. Endometriotic stromal cells show an abnormally low ESR1:ESR2 ratio due to excessive levels of ESR2, which mediates an estrogen-driven inflammatory process and prostaglandin formation. These cells are also deficient in PGR, leading to progesterone resistance and defective retinoid synthesis. The pattern of NR expression, involving low ESR1 and PGR and high ESR2, is reminiscent of uterine leiomyoma stem cells. This led us to speculate that endometriotic stromal cells may display stem cell characteristics found in other uterine tissues. The biologic consequences of these abnormalities in endometriotic tissue include intense inflammation, defective differentiation and enhanced survival.Steroid- and other NR-related abnormalities exert genome-wide biologic effects via interaction with defective epigenetic programming and enhance inflammation in endometriotic stromal cells. New synthetic ligands, targeting PGR, retinoic acid receptors and ESR2, may offer novel treatment options.
The Mechanosensitive Ion Channel Piezo Inhibits Axon Regeneration
Authors: Yuanquan Song, Dan Li, Olivia Farrelly, Leann Miles, Feng Li, Sung Eun Kim, Tsz Y. Lo, Fei Wang, Tun Li, Katherine L. Thompson-Peer, Jiaxin Gong, Swetha E. Murthy, Bertrand Coste, Nikita Yakubovich, Ardem Patapoutian, Yang Xiang, Panteleimon Rompolas, Lily Yeh Jan, Yuh Nung Jan
Journal: Neuron (2019)
Evaluating Treatment Effect of Transcatheter Interatrial Shunt Device Using Heart Failure Event Rates
Authors: Zachary R. McCaw, Dae Hyun Kim, Lee-Jen Wei
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Core-multishell nanocarriers enhance drug penetration and reach keratinocytes and antigen-presenting cells in intact human skin
Authors: Janna Frombach, Michael Unbehauen, Indah N. Kurniasih, Fabian Schumacher, Pierre Volz, Sabrina Hadam, Fiorenza Rancan, Ulrike Blume-Peytavi, Burkhard Kleuser, Rainer Haag, Ulrike Alexiev, Annika Vogt
Journal: Journal of Controlled Release (2019)
Chimeric antigen receptor T cells for acute lymphoblastic leukemia
Authors: Noelle V. Frey
Journal: American Journal of Hematology (2019)

Abstract Chimeric antigen receptor (CAR) modified T cells targeted to CD19 have resulted in unprecedented remission rates for adult and pediatric patients with relapsed and refractory B cell acute lymphoblastic leukemia (ALL). With regulatory approval for tisagenlecleucel and many other agents under active investigation, the use of CAR T cells for ALL continues to expand. While some remissions from anti‐CD19 CAR T cells are durable without a consolidative allogeneic stem cell transplantation, CD19 positive and negative relapses remain a significant concern fueling investigations into the biology of CAR T cell persistence and the development of CARTs that target more than 1 antigen. The treatment related toxicities of cytokine release syndrome and neurologic events are potentially life threatening but recent advances have improved understanding and management strategies. This review summarizes outcomes for patients with ALL treated with CD19‐CAR T cells while exploring the field's challenges and future directions.
Thunderclap Headache and Cerebral Vasoconstriction Secondary to Pheochromocytoma
Authors: Stephen W. English, Deena M. Nasr
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Radiomics on Gadoxetic Acid–Enhanced Magnetic Resonance Imaging for Prediction of Postoperative Early and Late Recurrence of Single Hepatocellular Carcinoma
Authors: Sungwon Kim, Jaeseung Shin, Do-Young Kim, Gi Hong Choi, Myeong-Jin Kim, Jin-Young Choi
Journal: Clinical Cancer Research (2019)

To evaluate the usefulness of the radiomic model in predicting early (≤2 years) and late (>2 years) recurrence after curative resection in cases involving a single hepatocellular carcinoma (HCC) 2-5 cm in diameter using preoperative gadoxetic acid-enhanced magnetic resonance imaging (MRI), in comparison with the clinicopathologic model.This retrospective study included 167 patients with surgically resected and pathologically confirmed single HCC 2-5 cm in diameter (n = 167, training set:validation set = 128:39) who underwent preoperative gadoxetic acid-enhanced MRI between January 2010 and December 2015. A radiomic model, a clinicopathologic model, and a combined clinicopathologic-radiomic (CCR) model were built using a random survival forest to predict disease-free survival (DFS) in the following conditions: early DFS versus late DFS, dynamic phases, and the peritumoral area included in the segmentation.The radiomic model showed a prognostic performance comparable with the clinicopathologic model only with 3-mm peritumoral border extension [c-index difference (radiomic-clinicopathologic), -0.021, P = 0.758]. The CCR model with the 3-mm border extension showed the highest c-index value but no statistically significant improvement over the clinicopathologic model [CCR, 0.716 (0.627-0.799); clinicopathologic model, 0.696 (0.557-0.799)].The prognostic value of the preoperative radiomic model with 3-mm border extension showed comparable performance with that of the postoperative clinicopathologic model for predicting DFS of early recurrence of HCC using gadoxetic acid-enhanced MRI. This suggests the importance of including peritumoral changes in the radiomic analysis of HCC.
Blockage of the serotonin transporter by fluoxetine is associated with inhibition of human melanoma invasion
Authors: Mingjie Ding, Ya-Min Fu, Yi-Qi Li, Robert Speth, Gary G. Meadows
Journal: Cancer Research (2004)

1856  Fluoxetine (ProzacTM) is a commonly used antidepressant drug. It selectively inhibits the reuptake of serotonin in neurons. The imaging agent, 5-iodo-2((2-((dimethylamino)methyl) phenyl)thio)-benzyl alcohol (IDAM), selectively binds to the serotonin transporter (SERT) in the cell membrane. We previously found that fluoxetine inhibited melanoma cell growth and metastastasis in vivo. In vitro the IC50 for fluoxetine is between 14-22 mM. Herein we evaluated the effect of fluoxetine on melanoma cell invasion and IDAM binding in the human melanoma cell lines, A375, Mewo and SB2. We found that all three melanoma cell lines specifically bound 125I labeled IDAM. The maximum binding (Bmax) ranged from 0.74 to 4.99 pmol/100,000 cells and the binding affinity (KD) ranged 10.6 to 38.7 nM. Fuoxetine competed for IDAM binding in the three melanoma cell lines and the IC50 ranged from 160 to 579 nM. Fluoxetine inhibited invasion of A375 melanoma at 1mM, which is ∼10-fold lower than the IC50 for growth inhibition. These data suggest that SERT is involved in inhibition of melanoma invasion. Moreover, the relative low concentration to inhibit melanoma invasion provides a strong rationale for using fluoxetine as part of a treatment regimen for melanoma patients.
Mobile teledermatology for melanoma detection: Assessment of the validity in the framework of a population-based skin cancer awareness campaign in northern Italy
Authors: Simone Cazzaniga, Emanuele Castelli, Anna Di Landro, Marco Di Mercurio, Gianlorenzo Imberti, Gustavo Andrea Locatelli, Francesca Raponi, Pamela Vezzoli, Daniele Gambini, Giovanni Damiani, Alberto Zucchi, Luigi Naldi
Journal: Journal of the American Academy of Dermatology (2019)
816. Development of Potent DNA Vaccines by Coupling of Linear MIDGE Vectors to Peptides
Journal: Molecular Therapy (2004)

The Sleeping Beauty (SB) transposon represents an important vehicle for in vivo gene delivery because it can stably integrate into the genomes of mammalian cells. Although SB is the most efficient non-viral integrating system described to date, all previous estimations of SB's integrative potential have relied on the use of antibiotic selection schemes. Previous work in other integrating systems (e.g. retroviruses) has demonstrated significant post-integrative gene silencing, leading us to investigate how genomic integration influences transposon expression in human cells. To do this we devised a new strategy to monitor SB integration that is not dependent on transgene expression. We constructed a single autonomously integrating plasmid (pT/YFP-SB) containing a YFP-marked transposon and an external plasmid-encoded transposase expression cassette, and transfected it into HeLa cells. Shortly thereafter, cells were single-cell sorted by FACS to generate a total of 183 clonal cell populations. Unexpectedly, after 6 weeks of growth (> 30 cell divisions) 28% of the cell lines continue to show stable transgene expression, as determined by fluorescence microscopy. We have begun screening these cell lines for the presence of transposon sequences by both PCR and Southern blot analyses, using various restriction enzymes to determine (i) the copy number and (ii) the molecular forms of the transposable element. Interestingly, preliminary results indicate that up to 15% of the total cell lines contain non-expressing integrated transgenes and we are currently investigating whether this may be due to post-integrative gene silencing. Surprisingly, up to 40% of the expressing cell lines contain persisting (non-dividing) episomal plasmid, as determined by DpnI/Southern blot analyses. Consequently, we are investigating whether co-delivery of SB and transposon sequences can facilitate episomal persistence in mammalian cells, possibly through transposase-mediated nuclear retention. Also of note, many individual cell lines showed heterogeneous YFP levels throughout the cell population. Currently, we are testing whether expression from an integrated transposon varies with the cell cycle, as has been seen in other integrating systems. The generation of stably silenced transposon clones provides an important new reagent to investigate the mechanism(s) by which integrating genetic elements (e.g. transposons and retroviruses) are silenced by the host cell, and should further our understanding of Sleeping Beauty biology.
Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening
Authors: Robert A Smith, Vilma Cokkinides, Durado Brooks, Debbie Saslow, Otis W Brawley
Journal: CA A Cancer Journal for Clinicians (2010)

Each year the American Cancer Society (ACS) publishes a summary of its recommendations for early cancer detection, a report on data and trends in cancer screening rates, and select issues related to cancer screening. In 2010, the ACS updated its guidelines for testing for early prostate cancer detection, and during 2009 there were several newsworthy updates in the cancer screening guidelines from other organizations. In this article, the current ACS guidelines and recent issues are summarized, updates of guidelines for testing for early breast cancer detection by the US Preventive Services Task Force and for prevention and early detection of cervical cancer from the American College of Obstetricians and Gynecologists are addressed, and the most recent data from the National Health Interview Survey pertaining to participation rates in cancer screening are described.
Renal globotriaosylceramide facilitates tubular albumin absorption and its inhibition protects against acute kidney injury
Authors: Ivan Morace, Robert Pilz, Giuseppina Federico, Richard Jennemann, Damir Krunic, Viola Nordström, Johanna von Gerichten, Christian Marsching, Ina Maria Schießl, Johannes Müthing, Christian Wunder, Ludger Johannes, Roger Sandhoff, Hermann-Josef Gröne
Journal: Kidney International (2019)

To elucidate the physiologic function of renal globotriaosylceramide (Gb3/CD77), which up-to-date has been associated exclusively with Shiga toxin binding, we have analyzed renal function in Gb3-deficient mice. Gb3 synthase KO (Gb3S-/-) mice displayed an increased renal albumin and low molecular weight protein excretion compared to WT. Gb3 localized at the brush border and within vesicular structures in WT proximal tubules and has now been shown to be closely associated with the receptor complex megalin/cubilin and with albumin uptake. In two clinically relevant mouse models of acute kidney injury caused by myoglobin as seen in rhabdomyolysis and the aminoglycoside gentamicin, Gb3S-/- mice showed a preserved renal function and morphology, compared to WT. Pharmacologic inhibition of glucosylceramide-based glycosphingolipids, including Gb3, in WT mice corroborated the results of genetically Gb3-deficient mice. In conclusion, our data significantly advance the current knowledge on the physiologic and pathophysiologic role of Gb3 in proximal tubules, showing an involvement in the reabsorption of filtered albumin, myoglobin and the aminoglycoside gentamicin.
Advanced imaging: the impressive success story of gastrointestinal endoscopy
Authors: Evelien Dekker, Ralf Kiesslich
Journal: Endoscopy (2019)

As we celebrate 50 years of Endoscopy, it is almost 70 years since the gastrocamera was first introduced. In 1950 it became possible to visualize the inside of the stomach by a stiff and long instrument with a photocamera on the tip. This gastrocamera was developed by Uji in collaboration with engineers from Olympus Optical Company of Tokyo, Japan. Imaging was not performed in real time, but pictures were taken blindly in a structured manner and then developed afterwards. This method meant that certain parts of the stomach were very difficult to visualize. In the subsequent years, the gastrocamera was gradually developed further, and in 1972, a new prototype was presented by Chang, which included two bending sections and other new features such as a close-up warning system and a fixed-volume air-pumping system [1]. In the meantime, a fiberoptic endoscope was developed, enabling real-time visualization of the gastrointestinal (GI) tract. However, quality was still quite poor and only one or two endoscopists could view at the same time. An extra side-viewer was needed for the second examiner, but this reduced the brightness of the view as this was divided into two. Even with this rather simple fiberoptic instrument, magnification became possible [2].
Behavior-Changing Interventions for Treating Overweight or Obesity in Children Aged 6 to 11 Years
Authors: Tamara J. Brown, Emma Mead, Louisa J. Ells
Journal: JAMA Pediatrics (2019)

<h3>Clinical Question</h3> How effective are diet, physical activity, and behavioral interventions in treating children aged 6 to 11 years with overweight or obesity? <h3>Bottom Line</h3> Multicomponent behavior-changing interventions may be beneficial in achieving small, short-term reductions in body mass index (calculated as weight in kilograms divided by height in meters squared), body mass index<i>z</i>score, and weight in children aged 6 to 11 years. Adverse events, health-related quality of life, behavior change outcomes, and sociodemographics were poorly or inconsistently reported. Overall, the quality of the evidence was low or very low, with no evidence from lower-income countries.